0G99

Noticias Thrombogenics Nv

Las mejores ofertas para acceder a los datos en tiempo real!
Real-time Level 1 for London Stock Exchange
Suscripción Mensual
Por sólo
US$29.56
Real-time Level 2 for London Stock Exchange
Suscripción Mensual
Por sólo
US$77.61
Real-time London Stock Exchange & FTSE
Suscripción Mensual
Por sólo
US$88.69
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Thrombogenics Nv 0G99 London Acción Ordinaria
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.0% 4.88 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.88 4.88
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
13/6/202212:00GLOBEOxurion Announces Two Presentations at The Macula Society..
07/6/202212:00GLOBEOxurion Announces Preclinical Presentation on THR-149 at..
03/6/202201:00GLOBEOxurion Announces Two Upcoming Presentations at The Macula..
01/6/202212:15GLOBEOxurion to Participate in Upcoming Investor Conferences
31/5/202212:00GLOBEInformation on the Total Number of Voting Rights..
25/5/202212:00GLOBEOxurion Announces Results of the Extraordinary Shareholders’..
24/5/202212:00GLOBEOxurion Announces Upcoming Preclinical Presentation on ..
09/5/202201:30GLOBEOxurion Announces Top-Line Results from Part A of Phase 2..
11/4/202200:00GLOBEOxurion Announces Upcoming Pre-Clinical Data Presentation on..
01/4/202212:00GLOBEOxurion Announces Extraordinary and Annual Shareholders’..
30/3/202212:00GLOBEInformation on the Total Number of Voting Rights..
28/3/202201:00GLOBEOxurion to Participate in Needham Virtual Healthcare..
25/3/202216:11GLOBEOxurion Publishes 2021 Annual Report
17/3/202213:00GLOBEOxurion Receives Transparency Notifications from Fidelity..
07/3/202203:00GLOBEOxurion Successfully Closes EUR >10 Million in Private..
03/3/202205:15GLOBEOXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM LEADING US..
03/3/202201:00GLOBEOXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM LEADING US..
22/2/202201:01GLOBEInformation on the Total Number of Voting Rights..
22/2/202201:00GLOBEOxurion NV announces 2021 Full Year Results and 2022 Outlook
14/2/202201:00GLOBEOxurion Announces New Data on THR-149 Phase 2 Clinical Trial..
11/2/202201:00GLOBEOxurion Announces Upcoming Presentation on THR-149 Phase 2..
08/2/202201:00GLOBEOxurion to Participate in the 2022 BIO CEO and Investor..
18/1/202201:00GLOBEOXURION to Participate in the 10th edition of Degroof..
07/1/202200:00GLOBEOxurion Provides Update on Clinical Pipeline Progress
04/1/202211:00GLOBEOXURION to Present at the H.C. Wainwright BioConnect 2022..
30/11/202100:00GLOBEInformation on the Total Number of Voting Rights..
24/11/202100:30GLOBEOXURION to Present at the Ophthalmology Day at BTIG
22/11/202100:00GLOBEOXURION NV Secures EUR 10 Million Convertible Bond Financing..
15/11/202100:00GLOBEOXURION NV - First Patient Dosed in Part B of Phase 2..
04/11/202101:00GLOBEOxurion NV Announces Initiation of Equity Analyst Coverage..
13/10/202100:00GLOBEOxurion NV Announces First Patient Dosed in its Phase 2..
11/10/202100:00GLOBEOXURION - Positive Phase 2 Part A THR-149 data shared at the..
30/9/202100:00GLOBEOXURION Announces Positive Results from Part A of Phase 2..
09/9/202112:00GLOBEOxurion NV Business & Financial Update – H1 2021
Su Consulta Reciente
LSE
0G99
Thrombogen..
Regístrese ahora para ver estas acciones en su Monitor streaming ADVFN.

Usted puede agregar y ver hasta 110 símbolos de sus acciones favoritas al mismo tiempo y completamente gratis.

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

P: V: D:20220625 12:00:15